Aug. 8 at 1:22 PM
$VTR delivered better-than-expected Q2 results, prompting its share price to rise 1.1% in the following trading session. Primarily due to higher outpatient medical and research portfolio revenues, as well as growth in resident fees and services, the company’s overall revenue grew 18.3% year-over-year to
$1.4 billion, surpassing consensus estimates by 3.6%. Furthermore, its adjusted same-store cash NOI advanced 6.6% from the year-ago quarter, reaching
$485.3 million. In comparison, its normalized FFO per share of
$0.87 improved 8.8% from the same period last year and came in 2.4% above analyst forecasts.
For the current fiscal year, ending in December, analysts expect Ventas’ FFO to grow 7.8% year over year to
$3.44 per share. The company’s earnings surprise history is promising. It exceeded or met the consensus estimates in each of the last four quarters.
